Evidence map›Paper›PMID 32579549›Full record

Trial reportPloS one2020

A novel nutritional supplement containing amino acids and chromium decreases postprandial glucose response in a randomized, double-blind, placebo-controlled study.

Elin Östman, Azat Samigullin, Lovisa Heyman-Lindén, Kristina Andersson, Inger Björck, Rickard Öste, Per M Humpert

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03152682 (A Multi-centre Randomized, Double-blind, Placebo-controlled, Crossover, Proof-of-concept Study to Evaluate the Efficacy and Safety of Good IdeaTM on Glucose Homeostasis in a Healthy Population), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03152682 phase1completednot on this map

A Multi-centre Randomized, Double-blind, Placebo-controlled, Crossover, Proof-of-concept Study to Evaluate the Efficacy and Safety of Good IdeaTM on Glucose Homeostasis in a Healthy Population

TypeinterventionalSponsorDoubleGood ABRan2017 to 2017Enrolled60ConditionsHealthyArmsGoodIdea, Placebo
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Elin ÖstmanFood for Health Science Center, Lund University, Lund, Sweden.ORCID 0000-0003-0831-6176
Azat SamigullinStarScience GmbH, Heidelberg, Germany.
Lovisa Heyman-LindénAventure AB, Lund, Sweden.
Kristina AnderssonAventure AB, Lund, Sweden.
Inger BjörckFood for Health Science Center, Lund University, Lund, Sweden.
Rickard ÖsteFood for Health Science Center, Lund University, Lund, Sweden.
Per M HumpertStarScience GmbH, Heidelberg, Germany.
Lund University · SEAventure (Sweden) · SEHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High postprandial blood glucose levels are associated with increased mortality, cardiovascular events and development of diabetes in the general population. Interventions targeting postprandial glucose have been shown to prevent both cardiovascular events and diabetes. This study evaluates the efficacy and safety of a novel nutritional supplement targeting postprandial glucose excursions in non-diabetic adults. Sixty overweight healthy male and female participants were recruited at two centers and randomized in a double-blind, placebo-controlled, crossover design. The supplement, a water-based drink containing 2.6g of amino acids (L-Leucine, L-Threonine, L-Lysine Monohydrochloride, L-Isoleucine, L-Valine) and 250 mcg of chromium picolinate, was consumed with a standardized carbohydrate-rich meal. The primary endpoint was the incremental area under the curve (iAUC) for venous blood glucose from 0 to 120 minutes. Secondary endpoints included glucose iAUC 0-180 minutes and the maximum glucose concentration (Cmax), for both venous and capillary blood glucose. In the intention-to-treat-analysis (n = 60) the supplement resulted in a decreased venous blood glucose iAUC0-120min compared to placebo, mean (SE) of 68.7 (6.6) versus 52.2 (6.8) respectively, a difference of -16.5 mmol/L•min (95% CI -3.1 to -30.0, p = 0.017). The Cmax for venous blood glucose for the supplement and placebo were 6.45 (0.12) versus 6.10 (<0.12), respectively, a difference of -0.35 mmol/L (95% CI -0.17 to -0.53, p<0.001). In the per protocol-analysis (n = 48), the supplement resulted in a decreased Cmax compared to placebo from 6.42 (0.14) to 6.12 (0.14), a difference of -0.29 mmol/L (95% CI -0.12 to -0.47, p = 0.002). No significant differences in capillary blood glucose were found, as measured by regular bed-side glucometers. The nutritional supplement drink containing amino acids and chromium improves the postprandial glucose homeostasis in overweight adults without diabetes. Future studies should clarify, whether regular consumption of the supplement improves markers of disease or could play a role in a diet aiming at preventing the development of diabetes.

Indexed as

AdolescentAdultAmino AcidsChromiumDietary SupplementsDouble-Blind MethodFemaleGlucoseHumansMaleMiddle AgedPlacebosPostprandial PeriodYoung AdultAmino AcidsChromiumGlucosePlacebos

Identifiers

PMID32579549
PMCPMC7313729
OpenAlexW3037884481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.